Zhitong Finance App News, Tianjin Development (00882) issued an announcement. Recently, Tianjin Central Pharmaceutical Co., Ltd. (“Central Pharmaceutical”), a wholly-owned subsidiary of the company's non-wholly-owned subsidiary, Tianjin Lisheng Pharmaceutical Co., Ltd. (hereinafter referred to as the “Company”) received a civil ruling No. 21 from the Tianjin Higher People's Court (2024). The court decided against Beijing Jinyang Licang Pharmaceutical Co., Ltd. (currently renamed: Beijing Kaianrui Pharmaceutical Management Co., Ltd., hereinafter referred to as “Kaianrui Pharmaceutical”).

The specific ruling results are as follows:

1. Annulment of the Tianjin Second Intermediate People's Court (2023) Tianjin 02 Minchu Civil Judgment No. 298;

2. The case was sent back to Tianjin No. 2 Intermediate People's Court for retrial.